Itamar Borochov
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid based cancer medicine, today announced that it has appointed the Company's Founder as a new Director and Member of its Board.
Itamar Borochov, 62, is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies which operate in regulated markets. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and Co-Founder, said, "The entire team is pleased to have Itamar return to the Board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases."
Mr. Borochov said: "The company's shareholders requested that I become reengaged and join the Board, to which I immediately agreed. At this point the company's groundbreaking research is moving into a go-to market strategy phase, through various collaborations. My immediate goal is to assist and facilitate these collaborations, which will bring us closer to realizing our vision of personalizing regulated medical cannabinoid-based cancer treatments."
Mr. Borochov's appointment to the board of directors was reported in the company's latest 8-K, filed on October 3rd, 2019.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.
For more information, please visit www.Cannabics.com.